Trinity Capital backs Monteris Medical with $35m to scale NeuroBlate brain surgery technology

Trinity Capital Inc. has committed $35 million in growth capital to Monteris Medical, a medical technology company developing minimally invasive neurosurgical systems. The financing is intended to support the continued commercialization of the NeuroBlate System and expand clinical research programs focused on brain tumors, radiation necrosis, and drug resistant epilepsy.

The financing signals growing investor confidence in advanced surgical technologies that promise to reduce complications, shorten hospital stays, and improve outcomes for patients with complex neurological conditions. As hospitals and surgeons increasingly adopt minimally invasive techniques, companies developing precision tools for delicate procedures such as brain surgery are attracting greater attention from private credit providers and strategic investors.

For Trinity Capital Inc., which specializes in providing structured capital to growth stage companies across technology and life sciences sectors, the Monteris Medical transaction represents another move into high value medical innovation markets. For Monteris Medical, the funding offers additional financial flexibility as it expands the commercial footprint of its flagship neurosurgical technology.

Why Trinity Capital Inc. is financing Monteris Medical’s expansion in neurosurgical technology

Trinity Capital Inc. operates in the rapidly expanding private credit segment, a financing market that has become increasingly important for high growth companies that may not yet fit the traditional lending criteria of commercial banks. The company structures financing solutions across several lending categories including sponsor finance, technology lending, asset based lending, equipment finance, and life sciences lending.

The decision to extend growth capital to Monteris Medical reflects the lender’s strategy of backing companies that have already developed commercial products but require additional capital to accelerate expansion. Monteris Medical fits that profile because the company’s NeuroBlate System is already being used in neurosurgical procedures and has demonstrated clinical utility in treating several complex neurological conditions.

Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital Inc., said the company believes Monteris Medical is driving innovation within the life sciences sector through technology that expands treatment options for neurosurgical patients. He stated that Trinity Capital Inc. is proud to support a team that continues pushing the boundaries of medical technology while delivering meaningful treatment solutions for patients.

Private credit providers often prefer companies with proven technologies that are already generating clinical data and physician adoption. In the current investment environment, this reduces risk compared with earlier stage medical technology startups that remain dependent on lengthy regulatory approval pathways or untested market demand.

How the NeuroBlate System is changing the approach to minimally invasive brain surgery

The core of Monteris Medical’s strategy revolves around the NeuroBlate System, a robotically controlled laser interstitial thermal therapy platform designed to treat abnormal brain tissue through a minimally invasive approach. Laser interstitial thermal therapy has gained attention in neurosurgery because it allows physicians to precisely destroy diseased tissue while minimizing damage to surrounding areas of the brain.

The NeuroBlate System uses MRI guidance and robotic control to deliver targeted laser energy directly to abnormal tissue. Surgeons can monitor the procedure in real time using magnetic resonance imaging, allowing them to adjust treatment parameters and ensure that thermal ablation remains within the intended treatment zone.

This precision is particularly important in brain surgery, where millimeters can determine whether healthy neurological function is preserved or compromised. Traditional open neurosurgery often requires larger incisions and longer recovery periods, while laser based approaches allow surgeons to access difficult to reach regions of the brain through smaller entry points.

Monteris Medical says the NeuroBlate System is used in treating conditions such as primary brain tumors, metastatic brain tumors, radiation necrosis caused by prior cancer treatments, and certain forms of drug resistant epilepsy. By destroying targeted brain tissue that causes seizures or tumor growth, the technology provides a potential alternative to conventional surgical approaches that require removing larger sections of tissue.

Another distinguishing feature of the NeuroBlate platform is its robotic interface, which allows surgeons to control laser placement with a high degree of precision. Monteris Medical states that the platform is the only laser interstitial thermal therapy system equipped with robotic targeting capabilities designed to ensure safe and accurate delivery of laser energy.

Clinical data from multicenter studies suggest that patients treated with the NeuroBlate System often experience shorter hospital stays and lower complication rates compared with open neurosurgical procedures. Patients may also return more quickly to normal activities because minimally invasive techniques reduce surgical trauma.

Why minimally invasive neurosurgery is becoming a major focus of medical technology investment

The global neurosurgery market has been steadily evolving as hospitals seek technologies that improve patient outcomes while reducing costs associated with long hospital stays and complex recovery periods. Minimally invasive surgical systems are emerging as a central part of this transformation.

Procedures involving the brain are among the most technically challenging operations performed in medicine. Surgeons must operate in extremely delicate environments where even small errors can result in serious neurological damage. Technologies that enhance precision and visualization therefore offer substantial clinical value.

Laser based therapies have become one of the fastest growing segments within neurosurgical innovation. Instead of physically removing tumors or diseased tissue through large surgical openings, surgeons can insert small probes into the brain and use controlled heat to destroy targeted tissue.

This approach has several potential advantages. It can reduce bleeding, lower infection risk, and shorten recovery times. Hospitals may also benefit from reduced operating room time and shorter patient stays, which can improve overall efficiency within neurosurgical departments.

Because of these benefits, investors are increasingly paying attention to companies developing precision surgical technologies. The combination of robotics, advanced imaging, and thermal therapies is creating new treatment possibilities for conditions that were historically difficult to treat safely.

How Monteris Medical plans to use the new growth capital

The $35 million financing facility from Trinity Capital Inc. is expected to support multiple strategic initiatives within Monteris Medical. The company intends to accelerate commercialization of the NeuroBlate System while continuing to expand its clinical research efforts.

Commercial expansion typically involves increasing sales infrastructure, training surgeons to use new technologies, and expanding relationships with hospitals and neuroscience centers. For a medical technology company operating in a specialized surgical field, physician training programs and clinical support teams are critical to ensuring successful adoption.

Clinical research will also remain a central focus. Continued clinical studies allow companies like Monteris Medical to generate evidence supporting the effectiveness and safety of their technologies. Published clinical data often plays a major role in persuading hospitals and surgeons to adopt new medical devices.

Martin J Emerson, President and Chief Executive Officer of Monteris Medical, said that securing the credit facility from Trinity Capital Inc., combined with support from Series E equity investors, strengthens the company’s ability to accelerate growth. He stated that the financing demonstrates confidence in the NeuroBlate platform and the company’s long term strategy to deliver innovative neurosurgical solutions.

According to Emerson, the financing will allow Monteris Medical to invest further in product innovation, commercial expansion, and the teams responsible for delivering its medical technologies to patients.

What this financing reveals about trends in medical technology funding

The Trinity Capital Inc. financing highlights a broader shift occurring in the medical technology funding landscape. During the past decade, venture capital played a dominant role in supporting medical device startups. However, as companies mature and move toward commercial scale, private credit has become an increasingly important financing source.

Growth stage companies often seek non dilutive capital solutions that allow them to expand operations without issuing large amounts of new equity. Debt financing can be attractive in these circumstances because it allows founders and early investors to retain greater ownership stakes while still accessing capital needed for expansion.

Private credit firms like Trinity Capital Inc. have stepped into this gap by offering flexible lending solutions tailored to the needs of high growth technology and life sciences companies. These lenders are willing to structure loans based on intellectual property, commercial traction, and future revenue potential rather than traditional collateral.

At the same time, investors are becoming more selective about which medical technology companies receive funding. Technologies must demonstrate strong clinical value and a clear path to market adoption in order to attract growth capital. The Monteris Medical transaction suggests that platforms combining robotics, imaging, and minimally invasive treatment methods continue to meet these criteria.

The future outlook for minimally invasive brain surgery technologies

Looking ahead, technologies like the NeuroBlate System are likely to play an increasingly prominent role in neurosurgical care. Advances in imaging, robotics, and energy based therapies are enabling surgeons to treat conditions that once required highly invasive procedures.

Researchers are also exploring new applications for laser interstitial thermal therapy in neurological disorders beyond tumors and epilepsy. Future studies may examine the technology’s potential in treating movement disorders, certain psychiatric conditions, or other neurological diseases where targeted tissue ablation could provide therapeutic benefits.

At the same time, the success of these technologies will depend on continued clinical validation and physician adoption. Neurosurgery is a highly specialized discipline, and new surgical tools must demonstrate clear advantages over established techniques before they become widely used.

The investment from Trinity Capital Inc. gives Monteris Medical additional resources to pursue that goal. If the company successfully expands adoption of the NeuroBlate System and continues generating positive clinical evidence, it could strengthen its position within the rapidly evolving neurosurgical technology market.

From an investor perspective, the deal also illustrates the growing importance of private credit in supporting innovation across the healthcare industry. As medical technologies become more sophisticated and development timelines lengthen, specialized financing providers are playing an increasingly important role in enabling companies to bring new treatments to patients.

For both Trinity Capital Inc. and Monteris Medical, the financing represents more than a simple funding transaction. It reflects the continued convergence of finance, technology, and medicine as the healthcare sector seeks more precise and less invasive ways to treat some of the most challenging diseases affecting the human brain.

Key takeaways on what Trinity Capital Inc.’s Monteris Medical financing means for medtech investors and industry watchers

• Trinity Capital Inc. is signaling that private credit still has appetite for commercial-stage medtech companies with tangible products and clinical validation.

• Monteris Medical appears to be moving from technology story to scale-up story, which is usually the point where structured debt becomes more attractive.

• The $35 million facility is less about survival capital and more about accelerating commercialization, product investment, and evidence generation.

• NeuroBlate’s appeal lies in multi-indication potential across brain tumors, radiation necrosis, and epilepsy, which strengthens platform economics.

• The financing suggests lenders increasingly prefer device companies with marketed systems over earlier-stage businesses with purely developmental risk.

• For Trinity Capital Inc., the deal supports its positioning as a specialized lender capable of underwriting technically complex healthcare borrowers.

• For Monteris Medical, the biggest challenge remains execution inside neurosurgery, where adoption depends on data, training, hospital economics, and workflow fit.

• TRIN stock’s recent short-term softness suggests the market sees this as steady portfolio deployment rather than an immediate valuation-changing event.

• If Monteris Medical converts this capital into stronger utilization and broader clinical credibility, the financing could prove strategically more important than its size implies.

• The broader industry takeaway is clear: in 2026, medtech capital is still available, but only for companies that can pair innovation with commercial proof.